Local 12, WCPO highlight brain tumor vaccine trial

Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor. 

The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.

In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.

"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.

Watch the Local 12 story.

Read the WCPO story.

Read more about the trial.

Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.

Related Stories

1

Inside UC’s Rhetoric & Professional Writing Program

November 18, 2025

Professional writers are the artists who bring the science of business, technology, and discoveries to life. They are storytellers who break down complex stories for everyday readers. The University of Cincinnati’s Rhetoric and Professional Writing (RPW) program in the College of Arts and Sciences gives students real-world experience from day one – an approach that helped recent grad, Olivia Hoge, turn her capstone work into her new career.

2

CCM actors build skills for the digital age

November 18, 2025

The BFA Acting program at UC's College-Conservatory of Music prepares students for careers in theatre and beyond in the evolving entertainment landscape. The Cincinnati Business Courier highlights the program's work in UC's Digital Performance Lab, showcasing how CCM's performance training embraces innovation in the digital era.